10 October 2011
The newly strengthened Azelis Pharma team will be on stand number 50, D35 to discuss our enhanced offering and new opportunities
Pharmaceuticals represents an important sector to Azelis and with the acquisition of the S&D Group our position has been bolstered providing an even stronger platform from which to serve our customers and suppliers. Neil Berry, International Business Director for Life Sciences, said: “2011 saw a step change for Azelis Pharma with the S&D acquisition. By integrating the businesses we benefit from an additional 50% sales, an enhanced geographic reach and a strong experienced team. We have a number of exciting new opportunities to pursue, both in terms of market and product range”.
Our existing Western European coverage has now been extended to be fully pan-European, including Bulgaria, Czech Republic, Hungary, Poland, Romania, Russia and Slovakia. However in addition to our strength and new infrastructure in Central and Eastern Europe, our footprint now extends beyond Europe with local offices and presence in Africa, Australia, Canada, China and India.
The S&D acquisition brings new supplier relationships with global leaders in both APIs and excipients. We will look to develop these relationships and offer our customers a much enhanced range. We have also identified new market opportunities in the veterinary market and are looking to exploit these in the future.
All S&D businesses in food, pharma, personal care and industrials chemicals are now successfully integrated into the relevant Azelis International Business Areas . Our new structure will enable us to centralise and consolidate our sourcing and purchasing, whilst staying close to the market with our local sales expertise.
In order to support our principals and our customers most effectively, we have created 2 new roles within the team. Matthew Dickman is International Business Manager responsible for APIs and Claus Nielutz is International Business Manager responsible for excipients. In their new roles, Matthew and Claus will optimise the product range portfolio for each region, identify and address gaps in the portfolio and service, provide existing suppliers with opportunities on wider geographic basis and work closely with multi-regional customers. We also intend to maintain continuity wherever appropriate and to this end Daren Norris, ex S&D Director for Eastern Europe and Russia, will lead the Azelis Pharma business in the CEE and Med East regions. Kevin Allen, formerly Vice President of S&D Canada, will head up the Azelis Canada operation.
The Azelis Pharma team look forward to meeting you at CPhI and discussing new opportunities with you.